<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968393</url>
  </required_header>
  <id_info>
    <org_study_id>2019-ASPIREAF</org_study_id>
    <secondary_id>2019-001336-62</secondary_id>
    <nct_id>NCT03968393</nct_id>
  </id_info>
  <brief_title>The ASPIRE-AF Trial</brief_title>
  <acronym>ASPIRE-AF</acronym>
  <official_title>Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative Atrial Fibrillation After Noncardiac Surgery - The ASPIRE-AF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study of oral anticoagulation versus no anticoagulation for the prevention of stroke
      and other adverse cardiovascular events in patients with transient perioperative atrial
      fibrillation after noncardiac surgery and additional stroke risk factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASPIRE-AF is a prospective, randomized, open-label trial to assess the feasibility of a
      randomized controlled trial of non-vitamin K oral anticoagulants (NOACs) versus no
      anticoagulation in patients with transient perioperative atrial fibrillation after noncardiac
      surgery and additional stroke risk factors. The primary objective is to assess the
      feasibility of a randomized controlled trial of NOACs versus no anticoagulation in patients
      with perioperative atrial fibrillation after noncardiac surgery and additional stroke risk
      factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, open-label clinical trial with blinded outcome assessment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants to Complete Recruitment</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
    <description>Recruit 100 patients at an average recruitment rate of 1 patient per centre per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants to Complete Follow-up</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
    <description>Achieve complete follow-up on 90% more of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Resource Requirement</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
    <description>Determine resource requirements to achieve recruitment and follow-up goals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Drug Adherence</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
    <description>Determine feasibility of administering oral anticoagulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non-hemorrhagic stroke or systemic embolism</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause mortality</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Vascular mortality</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myocardial infarction</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Symptomatic venous thromboembolism</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalization for congestive heart failure</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Tertiary objective: Montreal Cognitive Assessment</measure>
    <time_frame>Baseline, 1 year (if applicable), final follow-up</time_frame>
    <description>Effects of NOACs on the change in Montreal Cognitive Assessment scores (range between 0-30 points)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety objective: incidence of composite of life-threatening, major, and critical organ bleeding</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
    <description>as previously used in the MANAGE trial</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety objective: incidence of major bleeding</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
    <description>According to the ISTH criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety objective: incidence of hemorrhagic stroke</measure>
    <time_frame>Up to 24 months, until final follow-up</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Non-vitamin K oral anticoagulant (NOAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No anticoagulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients allocated to the no anticoagulation arm are not allowed to receive oral anticoagulation, unless the patient develops an indication for its use during follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigators can choose from one of four Non-vitamin K oral anticoagulants (NOACs): Edoxaban 60mg daily, Apixaban 5mg twice daily, Dabigatran 110mg twice daily, or, Rivaroxaban 20mg daily.</intervention_name>
    <description>Daily administration from time of randomization to final follow-up</description>
    <arm_group_label>Non-vitamin K oral anticoagulant (NOAC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. noncardiac surgery with at least an overnight hospital admission after surgery in the
             last 35 days;

          2. ≥1 episode of clinically significant perioperative AF;

          3. sinus rhythm at the time of randomization; AND

          4. any of the following high-risk criteria:

               1. age ≥55 years, and having either known cardiovascular disease, recent major
                  vascular surgery, or a CHA2DS2VASc score ≥3;

               2. age ≥65 and a CHA2DS2VASc score**** ≥2; OR

               3. age ≥75 years.

        Exclusion Criteria:

          1. history of documented AF prior to noncardiac surgery;

          2. need for long-term systemic anticoagulation;

          3. ongoing need for long-term dual antiplatelet treatment;

          4. contraindication to oral anticoagulation;

          5. severe renal insufficiency (eGFR &lt;30 ml/min);

          6. acute stroke in the past 3 months;

          7. underwent cardiac surgery in the past 3 months;

          8. history of intracranial, intraocular, or spinal bleeding;

          9. hemorrhagic disorder or bleeding diathesis;

         10. expected to be non-compliant with follow-up and/or study medications;

         11. known life expectancy less than 1 year due to concomitant disease;

         12. women who are pregnant, breastfeeding, or of childbearing potential; OR

         13. previously enrolled in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Conen, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PJ Devereaux, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Makayla Tosh</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>41153</phone_ext>
    <email>aspireaf@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transient Atrial Fibrillation</keyword>
  <keyword>Perioperative Atrial Fibrillation</keyword>
  <keyword>Non-vitamin K Oral Anticoagulation</keyword>
  <keyword>Noncardiac Surgery</keyword>
  <keyword>PROBE Design</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

